UK Updates Guidance To Reflect EU Medtech Extensions - Pledges Focus On Agility, Innovation
MPs Urge Right Kind Of Medtech Regulations
The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.
You may also be interested in...
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.
When it comes to medtech adverse events incidents may not always be obvious. This is especially the case with medical device software where indirect harm is the most likely outcome of an incident, the UK’s MHRA explains in new guidance.
The UK government has proposed a “pro-innovation” AI regulation strategy, which will utilize the expertise of existing regulators and avoid new legislation. But what does this mean for the medtech sector, and how does the UK approach differ from the EU’s AI Act?